Press Releases Eagle Pharmaceuticals, Inc.

Equities

EGRX

US2697961082

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
4.55 ^USD	+1.56%		+15.19%	-13.00%

15/05	Eagle Pharmaceuticals, Inc. Enters into a Third Amendment to Third Amended and Restated Credit Agreement	CI
06/05	North American Morning Briefing : Stock Futures -2-	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq	22/05	AQ
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting	30/04	AQ
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting	16/04	AQ
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K	15/04	AQ
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida	15/04	AQ
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K	13/04	AQ
EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options	09/02	PR
Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX	09/02	PR
EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit	09/02	PR
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)	09/02	BU
The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024	08/02	PR
Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX	08/02	PR
EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit	07/02	PR
Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline	06/02	PR
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX	03/02	PR
EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options	02/02	PR
The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)	02/02	PR
The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024	01/02	PR
EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit	31/01	PR
Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline	30/01	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Eagle Pharmaceuticals, Inc.

Equities

EGRX

US2697961082

Press Releases

Filters